BioSpace News Archive

Oska Wellness has released the results of a randomized double-blind placebo study showing significant results in pain reduction by using Oska Pulse.

Mr. Gibney is a highly experienced life sciences-focused investment banker and has executed over 150 financings and M&A advisory transactions for US and European clients.

The new online platform allows users to input search parameters by utilizing one of two molecular structure drawing tools provided on the site, or by uploading search data files.

Treatment with EGFR TKIs such as erlotinib, gefitinib, or afatinib is used as first-line therapy for metastatic EGFR-mutated NSCLC.

Dr. Nuttall joins Kymera from Sanofi Genzyme where he led business development and licensing for Immunology and Inflammation and Neuroscience.

BodyNav leverages the existing on-board sensors of smartphones and advanced 3D headsets in novel and unanticipated ways to engage the body’s innate center of gravity.

Aperio Clinical Outcomes provides both comprehensive and customizable clinical research services across multiple therapeutic areas.

Tenax Therapeutics announced the appointment of three internationally recognized medical experts in the fields of pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF) to its Scientific Advisory Board for the company’s planned Phase 2 clinical study in the use of levosimendan for patients with PH-HFpEF.

Allurion Technologies today announces the start of ENLIGHTEN, a United States clinical trial for the Elipse Balloon – the world’s first and only procedureless™ gastric balloon for weight loss.

The most common adverse reactions during clinical trials were injection-site pain and headache.